Rigel Pharmaceuticals Appoints Alison L. Hannah as Chief Medical Officer

Rigel Pharmaceuticals announced the appointment of Alison L. Hannah, to the role of Executive Vice President and Chief Medical Officer. Hannah has resigned from Rigel's Board of Directors, effective July 1, in connection with her appointment. She succeeds Lisa Rojkjaer, as Chief Medical Officer. Alison L. Hannah has held the roles of Chief Medical Officer of CytomX Therapeutics, where she oversaw clinical development of conditionally activated protein therapeutics, and Senior Medical Director at SUGEN where she had oversight of clinical development, clinical operations, and pharmacovigilance, specializing in the development of tyrosine kinase inhibitors, including sunitinib approved for the treatment of kidney cancer and imatinib-refractory gastrointestinal stromal tumors. Hannah has served as a consultant to the pharmaceutical and biotechnology industry since 2000, directing the development of investigational cancer therapies. Hannah received her B.A. in biochemistry and immunology from Harvard University and her M.D. from the University of St Andrews. Rigel's leading pipeline asset, R2891, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4, continues to be advanced in its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with relapsed or refractory lower-risk myelodysplastic syndrome.